Cypress Capital Group Has $534,000 Position in Becton, Dickinson and Company $BDX

Cypress Capital Group reduced its holdings in shares of Becton, Dickinson and Company (NYSE:BDX) by 4.6% during the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 3,098 shares of the medical instruments supplier’s stock after selling 150 shares during the period. Cypress Capital Group’s holdings in Becton, Dickinson and Company were worth $534,000 at the end of the most recent reporting period.

Several other institutional investors have also made changes to their positions in BDX. Saudi Central Bank acquired a new position in Becton, Dickinson and Company in the first quarter valued at about $26,000. Smallwood Wealth Investment Management LLC acquired a new position in Becton, Dickinson and Company in the first quarter valued at about $27,000. Alpine Bank Wealth Management acquired a new position in Becton, Dickinson and Company in the first quarter valued at about $29,000. Cornerstone Planning Group LLC boosted its position in Becton, Dickinson and Company by 341.4% in the first quarter. Cornerstone Planning Group LLC now owns 128 shares of the medical instruments supplier’s stock valued at $29,000 after buying an additional 99 shares in the last quarter. Finally, Kelly Lawrence W & Associates Inc. CA acquired a new position in Becton, Dickinson and Company in the first quarter valued at about $31,000. 86.97% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling

In related news, Director Claire Fraser sold 917 shares of the business’s stock in a transaction that occurred on Wednesday, September 10th. The shares were sold at an average price of $187.50, for a total transaction of $171,937.50. Following the completion of the sale, the director directly owned 22,226 shares of the company’s stock, valued at $4,167,375. The trade was a 3.96% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, EVP Michael David Garrison sold 1,185 shares of the business’s stock in a transaction that occurred on Friday, July 18th. The stock was sold at an average price of $180.29, for a total transaction of $213,643.65. Following the sale, the executive vice president directly owned 4,887 shares of the company’s stock, valued at approximately $881,077.23. This trade represents a 19.52% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 3,023 shares of company stock valued at $562,036. 0.36% of the stock is currently owned by insiders.

Becton, Dickinson and Company Trading Up 0.1%

BDX opened at $186.76 on Tuesday. The company has a debt-to-equity ratio of 0.69, a current ratio of 1.10 and a quick ratio of 0.62. The company has a market cap of $53.53 billion, a price-to-earnings ratio of 33.59, a price-to-earnings-growth ratio of 1.46 and a beta of 0.25. The firm has a 50 day simple moving average of $190.23 and a 200 day simple moving average of $185.45. Becton, Dickinson and Company has a fifty-two week low of $163.33 and a fifty-two week high of $251.99.

Becton, Dickinson and Company (NYSE:BDX) last posted its quarterly earnings results on Thursday, April 14th. The medical instruments supplier reported $4.10 earnings per share for the quarter. The business had revenue of $5.32 billion during the quarter. Becton, Dickinson and Company had a net margin of 7.51% and a return on equity of 16.23%. On average, sell-side analysts anticipate that Becton, Dickinson and Company will post 14.43 earnings per share for the current year.

Becton, Dickinson and Company Dividend Announcement

The firm also recently declared a quarterly dividend, which was paid on Tuesday, September 30th. Investors of record on Monday, September 8th were paid a dividend of $1.04 per share. This represents a $4.16 dividend on an annualized basis and a dividend yield of 2.2%. The ex-dividend date of this dividend was Monday, September 8th. Becton, Dickinson and Company’s payout ratio is 74.82%.

Analyst Ratings Changes

A number of equities analysts have commented on the stock. Argus boosted their price target on shares of Becton, Dickinson and Company from $220.00 to $230.00 in a research report on Monday, September 15th. Wall Street Zen upgraded shares of Becton, Dickinson and Company from a “hold” rating to a “buy” rating in a research report on Saturday, August 9th. Piper Sandler restated a “neutral” rating and issued a $200.00 price target (up from $185.00) on shares of Becton, Dickinson and Company in a research report on Friday, August 8th. Morgan Stanley boosted their target price on shares of Becton, Dickinson and Company from $196.00 to $197.00 and gave the stock an “overweight” rating in a research note on Monday, August 11th. Finally, Wells Fargo & Company boosted their target price on shares of Becton, Dickinson and Company from $172.00 to $184.00 and gave the stock an “equal weight” rating in a research note on Friday, August 8th. Three equities research analysts have rated the stock with a Buy rating and nine have issued a Hold rating to the company’s stock. Based on data from MarketBeat.com, Becton, Dickinson and Company has a consensus rating of “Hold” and a consensus target price of $205.40.

About Becton, Dickinson and Company

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.